- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04847362
The Effect of Tele-Health Education Provided in the Postpartum Period in the Covid 19 Pandemic
22. november 2021 oppdatert av: YASEMİN AYDIN KARTAL, Saglik Bilimleri Universitesi
Investigation of the Effect of Tele-Health Education Provided in the Postpartum Period in the Covid 19 Pandemic on the Depression, Attachment and Anxiety Levels of Women: A Randomized Controlled Study
In the planned study, it was aimed to examine the effect of tele-education offered in the postpartum period in the covid 19 pandemic on the levels of depression, attachment and anxiety of women.
Studieoversikt
Status
Rekruttering
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
In the planned study, it was aimed to examine the effect of tele-education offered in the postpartum period in the covid 19 pandemic on the levels of depression, attachment and anxiety of women.
Studietype
Intervensjonell
Registrering (Forventet)
74
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
-
Istanbul, Tyrkia
- Rekruttering
- Sağlık Bilimleri Üniversitesi
-
Ta kontakt med:
- YASEMİN AYDIN KARTAL
- Telefonnummer: +90 5432870029
- E-post: yasemin.aydin@sbu.edu.tr
-
İstanbul, Tyrkia, 34668
- Rekruttering
- Zeynep Kamil Women's and Children's Diseases Training and Research Hospital
-
Ta kontakt med:
- LEYLA KAYA
- Telefonnummer: +90 5456439482
- E-post: leylakaya02@hotmail.com
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år til 35 år (Voksen)
Tar imot friske frivillige
Ja
Kjønn som er kvalifisert for studier
Hunn
Beskrivelse
inclusion Criteria
- literate
- Giving birth at term (between 38-42 weeks of gestation)
- Being on the 7th Postpartum Day,
- Participation in the study is voluntary,
- Absence of any psychiatric illness,
- Women who have characteristics such as not using any psychiatric medication.
- Baby with normal birth weight and APGAR score of 8 and above
- Those who have not developed postpartum complications
- Speaks and understands Turkish
Exclusion Criteria:
women who do not meet the sample selection criteria
-
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Experimental
The mothers in this group will be given telehealth training for 4 weeks.
|
education group
|
|
Ingen inngripen: Control
Mothers in this group will not be given telehealth education, they will receive care within the scope of routine care.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
postpartum depression
Tidsramme: postpartum 6 weeks
|
The Edinburgh Postnatal Depression Scale (EPDS) was used to detect depressive symptoms during the postpartum period [30].
EPDS is a 10-item questionnaire assessing the interviewee's depressive feelings from the seven days before the interview.
The response of the questions is scored from 0-3, with higher scores indicating higher levels of depressive symptoms.
The total EPDS score of a respondentcan range from 0 to 30.
|
postpartum 6 weeks
|
|
postpartum depression
Tidsramme: postpartum 3 months
|
The Edinburgh Postnatal Depression Scale (EPDS) was used to detect depressive symptoms during the postpartum period [30].
EPDS is a 10-item questionnaire assessing the interviewee's depressive feelings from the seven days before the interview.
The response of the questions is scored from 0-3, with higher scores indicating higher levels of depressive symptoms.
The total EPDS score of a respondentcan range from 0 to 30.
|
postpartum 3 months
|
|
postpartum mother-baby attachment
Tidsramme: postpartum 6 weeks a
|
Postpartum Attachment Scale: Early diagnosis of problems in mother-infant relationship Developed to provide and maternal filling4.
The scale is a six-digit It has a Likert scale.
Scale "always", Postpartum attachment scales in mothers 247 "Very often", "often", "sometimes", "rarely", "no It has been defined as "time".
Items 0-5 It is rated as.
Scale 17 is reverse It consists of 25 graded items.
Scale "attachment disorder" (12 items), "Rejection and irritability" (seven items), "care tension about "(four items), abuse four sub-categories with risk (two substances) It consists of units.
Pathology in mother-infant relationship cut point specified for four subscales 4'18 The cut-off point of four subscales attachment disorder (subscale 1), respectively> 12, rejection and irritability (subscale 2)> 17, anxiety in infant care (subscale 3)> 10, the risk of abuse (subscale 4) is> 3.
|
postpartum 6 weeks a
|
|
postpartum mother-baby attachment
Tidsramme: postpartum 3 months
|
Postpartum Attachment Scale: Early diagnosis of problems in mother-infant relationship Developed to provide and maternal filling4.
The scale is a six-digit It has a Likert scale.
Scale "always", Postpartum attachment scales in mothers 247 "Very often", "often", "sometimes", "rarely", "no It has been defined as "time".
Items 0-5 It is rated as.
Scale 17 is reverse It consists of 25 graded items.
Scale "attachment disorder" (12 items), "Rejection and irritability" (seven items), "care tension about "(four items), abuse four sub-categories with risk (two substances) It consists of units.
Pathology in mother-infant relationship cut point specified for four subscales 4'18 The cut-off point of four subscales attachment disorder (subscale 1), respectively> 12, rejection and irritability (subscale 2)> 17, anxiety in infant care (subscale 3)> 10, the risk of abuse (subscale 4) is> 3.
|
postpartum 3 months
|
|
anxiety state
Tidsramme: postpartum 6 weeks
|
State Anxiety Scale (STAI-I) in 1970 Turkish form developed by Spielberger Oner N et al.
Its validity and reliability study has been carried out by adapting it.
Anxiety level In STAI-I, "(1) not at all, (2) a little, (3) a lot and (4) completely" While it is scored as, the options in STAI-II are (1) almost never, (2) sometimes, (3) a lot of time, and (4) it is almost always.
2 kinds of scales Scores obtained from both scales theoretically it ranges from 20 to 80. High score indicates high anxiety level
|
postpartum 6 weeks
|
|
anxiety state
Tidsramme: postpartum 3 months
|
State Anxiety Scale (STAI-I) in 1970 Turkish form developed by Spielberger Oner N et al.
Its validity and reliability study has been carried out by adapting it.
Anxiety level In STAI-I, "(1) not at all, (2) a little, (3) a lot and (4) completely" While it is scored as, the options in STAI-II are (1) almost never, (2) sometimes, (3) a lot of time, and (4) it is almost always.
2 kinds of scales Scores obtained from both scales theoretically it ranges from 20 to 80. High score indicates high anxiety level
|
postpartum 3 months
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
11. april 2021
Primær fullføring (Forventet)
22. november 2021
Studiet fullført (Forventet)
30. januar 2022
Datoer for studieregistrering
Først innsendt
12. april 2021
Først innsendt som oppfylte QC-kriteriene
14. april 2021
Først lagt ut (Faktiske)
19. april 2021
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
23. november 2021
Siste oppdatering sendt inn som oppfylte QC-kriteriene
22. november 2021
Sist bekreftet
1. november 2021
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Atferdssymptomer
- Psykiske lidelser
- Coronavirus-infeksjoner
- Coronaviridae-infeksjoner
- Nidovirales infeksjoner
- RNA-virusinfeksjoner
- Virussykdommer
- Infeksjoner
- Luftveisinfeksjoner
- Sykdommer i luftveiene
- Stemningsforstyrrelser
- Lungebetennelse, viral
- Lungebetennelse
- Lungesykdommer
- Graviditetskomplikasjoner
- Puerperale lidelser
- Depresjon
- Depressiv lidelse
- Covid-19
- Angstlidelser
- Depresjon, postpartum
Andre studie-ID-numre
- 11.04.2021-27076
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
UBESLUTTE
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .